Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Biomolecular Holdings LLC maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 3 pending office actions, indicating an active prosecution phase. These actions are distributed across 2 distinct examiners, which suggests a concentration of work with specific individuals.
The busiest examiner identified for this portfolio is OUSPENSKI, ILIA I, who is responsible for 2 pending office actions. This means that OUSPENSKI, ILIA I handles 2 of the 3 pending actions currently on record for the company. The remaining pending office action is managed by the other of the 2 distinct examiners. This concentration requires practitioners to prioritize their relationship and communication with OUSPENSKI, ILIA I.
The prosecution activity spans 2 distinct art units. This distribution suggests that the Biotechnology & Pharmaceuticals innovations from Biomolecular Holdings LLC cover different technical sub-sectors. Practitioners must navigate the specific procedural nuances of 2 different art units while also managing the individual preferences of 2 separate examiners. The busiest examiner pending count of 2 is higher than the count for the other examiner involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 2 | 77.3% | +20.6% |
| REDDIG, PETER J | 1 | 58.0% | +40.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18153769 | TETRAHEDRAL ANTIBODIES | OUSPENSKI, ILIA I | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17545420 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | REDDIG, PETER J | 42d overdue |
| 18188412 | TOPOLOGICALLY ENGINEERED SUPERDIMERIC ANTIBODIES | OUSPENSKI, ILIA I | — |
| 18153769 | TETRAHEDRAL ANTIBODIES | OUSPENSKI, ILIA I | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18188412 | TOPOLOGICALLY ENGINEERED SUPERDIMERIC ANTIBODIES | OUSPENSKI, ILIA I | 1644 | §112DP | Non-Final OA | — | Pending | Mar 22, 2023 |
| 18153769 | TETRAHEDRAL ANTIBODIES | OUSPENSKI, ILIA I | 1644 | §101§102§112DP | Non-Final OA | — | Pending | Jan 12, 2023 |
| 17545420 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | REDDIG, PETER J | 1646 | §103 | Final Rejection | 42d overdue | Pending | Dec 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBiomolecular Holdings LLC has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Ilia I Ouspenski has the most, with 2 of Biomolecular Holdings LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
